the power of key business questions

The Power of Key Business Questions

In our biopharma world, we frequently hear the term “Key Business Questions (KBQs).” And while it’s often thrown around as a buzzword (or buzz phrase, in this case), it has quite a bit of practical value when its full depth is explored.

biopharma-annual-planning-close-rings

Biopharma Annual Planning Success: Close Your Rings Year-Round

How do we think about biopharma annual planning differently? The analogy I will draw on is fitness trackers and apps—built for mindfulness and exercise—these devices and apps create a habit for daily (weekly, monthly, etc.) self-challenges.

target-product-profiles

The Power of Target Product Profiles: Three Case Studies

In the biopharma industry, the Target Product Profile (TPP) is a critical tool for guiding the development and commercialization of new drugs.

Unlocking Success: The Power of Target Product Profiles

In the ever-evolving biopharma landscape, success hinges not just on innovation but also on a clear roadmap guiding clinical and commercial development.

Governance: The Glue to a Successful Launch

At the core of every successful launch lies a meticulously crafted plan, a robust governance structure, and expert management of its execution.

Your Data Needs a Strategy

In the not-so-distant past, physician prescribing data was essentially a commodity with limited breadth or depth for the purposes of drug development and commercialization. Two primary third-party providers aggregated data from essentially the same sources.

Juggling Geographic Commercialization Priorities

Commercializing a pharmaceutical asset in one country is hard enough. Doing it on a global scale, with multiple country differences, is exponentially more difficult.

Medical Affairs: An Orchestra, Not a Horse Race

Every horse race has a starting bell, a push to move as fast as possible, and a finish line. In many ways, the launch of a new drug can feel similar. But the metaphor only goes so far — launch preparation is not simply about speed, and in this case, the “horses” keep changing, and the track is anything but predictable.

A better metaphor is that of an orchestra, with many instruments contributing distinctly at specific times. All play the same piece of music but contribute based on their respective roles.

Three Big Mistakes

Over the past 20 years, The NemetzGroup has been involved in the launch of more than 50 different drugs and has had input into the strategic commercialization plans of many more. While no two launches are ever exactly the same — based on the team, company, and unmet need the drug hopes to address — there are certain patterns and similarities that we see repeating. Unfortunately, not all of these are positive.